Changchun BCHT Biotechnology Co.

Chinese manufacturers of novel vaccines have bolstered their efforts to pivot to emerging markets in 2024, amid challenges in the sector on the home front. While fierce domestic price wars, destockin

Multiple major Chinese vaccine manufacturers are expecting annual profits to have slumped in 2024, as fiercer competition, destocking at vaccination clinics and a slowing Chinese economy all weigh on

China’s first homegrown vaccine for herpes zoster (shingles), Ganwei, developed by Changchun BCHT Biotechnology Co. (BCHT), had a strong commercial launch in 2023, setting the stage for a showdown w

In China, speed matters. A fast launch and quick roll-out of a new drug or vaccine to patients who need it can sometimes make or break a product. In an eye-popping, three-year purchasing deal worth up